Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

BOSTON SCIENTIFIC CORPORATION

(BSX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Boston Scientific : Remote Monitoring Study Aims to Advance Care for Heart Patients with COVID-19

12/04/2020 | 12:39pm EST

A new study may help to better understand how the COVID-19 virus affects people with heart conditions or chronic illnesses and improve their health care.

In collaboration with Boston Scientific, a research team from Yale New Haven Hospital's Center for Outcomes Research & Evaluation (CORE) hopes to accomplish this by studying data from pacemakers and defibrillators remotely monitored by the LATITUDE™ Home Monitoring System in patients with COVID-19. The Boston Scientific devices in the study offer some of the most advanced heart rhythm management technologies available.

The LATITUDE system is an in-home device that provides physicians automatic, daily monitoring of cardiac devices implanted in patients. The system improves quality of care through earlier detection and treatment of heart problems; also, by reducing the need for in-office visits, it enhances patient convenience and safety and increases clinical efficiency.

The study was inspired by reports from the physicians that with the onset of COVID-19 some sensor data seen in the LATITUDE system changed in patients. By studying continuous sensor data from the implanted devices in patients before, during and after a COVID-19 infection, researchers hope to detect and anticipate which patients will need critical resources, such as intensive care.

'We know that patients with heart disease are at a much higher risk of developing more serious complications associated with COVID-19,' said Ken Stein, M.D., senior vice president and chief medical officer for Rhythm Management and Global Health Policy at Boston Scientific.

'Enabling better identification of the early onset of COVID-19 in this patient population and differentiating COVID-related symptoms from worsening cardiac disease may help reduce the burden on health care systems while improving outcomes for at-risk patients.'

The study, which is being led by Harlan M. Krumholz, MD, SM and Yuan Lu, ScD from the Yale University and Yale New Haven Hospital's CORE lab, was designed by the CORE lab in collaboration with Boston Scientific and will combine patient test results, symptoms and other information about their COVID-19 experience with monitoring data from their implanted device.

Physicians can direct their patients who are interested in participating to a website that includes eligibility criteria and basic information about the study. The study is open to anyone who has ever tested positive for COVID-19 and has a pacemaker or defibrillator remotely monitored by the LATITUDE™ system.

Patients can enroll in the trial by completing a short questionnaire about their COVID-19 symptoms and testing and general health information, which is securely protected using data encryption and access restrictions.

Ultimately, researchers hope to help healthcare professionals better remotely manage cardiac patients-especially those with multiple chronic conditions during and after the COVID-19 pandemic-improve outcomes among at-risk patients and reduce the overall burden on the health system.

Disclaimer

Boston Scientific Corporation published this content on 04 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 December 2020 17:38:02 UTC


© Publicnow 2020
All news about BOSTON SCIENTIFIC CORPORATION
01/22BOSTON SCIENTIFIC : Fourth-Generation Deep Brain Stimulation System Receives FDA..
MT
01/22BOSTON SCIENTIFIC : Gets FDA OK for Vercise Genus Deep Brain Stimulation System
DJ
01/22BOSTON SCIENTIFIC : Receives FDA Approval For The Vercise Genus™ Deep Brai..
PR
01/21BOSTON SCIENTIFIC : ROSEN, LEADING INVESTOR COUNSEL, Reminds Boston Scientific C..
PR
01/21BOSTON SCIENTIFIC : to Acquire Preventice Solutions for $925 Million Upfront
MT
01/21BOSTON SCIENTIFIC : to Buy Rest of Preventice Solutions
DJ
01/21BOSTON SCIENTIFIC CORP : Other Events, Financial Statements and Exhibits (form 8..
AQ
01/21BOSTON SCIENTIFIC : Announces Agreement To Acquire Preventice Solutions, Inc.
PR
01/20BOSTON SCIENTIFIC : The Law Offices of Frank R. Cruz Announces the Filing of a S..
PR
01/15GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
PR
More news
Financials (USD)
Sales 2020 10 046 M - -
Net income 2020 1,90 M - -
Net Debt 2020 7 923 M - -
P/E ratio 2020 -701x
Yield 2020 -
Capitalization 53 024 M 53 024 M -
EV / Sales 2020 6,07x
EV / Sales 2021 5,09x
Nbr of Employees 36 000
Free-Float 85,1%
Chart BOSTON SCIENTIFIC CORPORATION
Duration : Period :
Boston Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 43,12 $
Last Close Price 37,03 $
Spread / Highest target 35,0%
Spread / Average Target 16,4%
Spread / Lowest Target 5,32%
EPS Revisions
Managers and Directors
NameTitle
Michael F. Mahoney Chairman, President & Chief Executive Officer
Edward F. Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Ian T. Meredith Global Chief Medical Officer & Executive VP
Jodi Eddy Chief Information Officer & SVP
Sector and Competitors